MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Executive Officer Jorge Santos da Silva reported open-market sales of 150,000 Class A ordinary shares of the company. The transactions occurred on April 10 and April 13 at weighted average prices of $18.41 and $18.23 per share, respectively, in multiple trades within disclosed price ranges. Following these sales, he continues to hold 2,924,893 Class A ordinary shares directly. The sales were made pursuant to Rule 144 under the Securities Act, indicating resales of already-owned shares under an established exemption.

Insights

Equity ownership & governance analyst

CEO executes Rule 144 share sales while retaining a large stake.

The CEO of MoonLake Immunotherapeutics, Jorge Santos da Silva, sold a total of 150,000 Class A ordinary shares in two open-market transactions under Rule 144. Rule 144 permits resale of restricted or control securities subject to specific conditions.

After these sales, he directly holds 2,924,893 shares, so the filing shows a reduction but not an exit from his equity position. The trades used weighted average prices in ranges between $18.00 and $19.55, typical of multiple executions across the market on each day.

The transactions consist solely of non-derivative share sales, with no option exercises or derivative conversions reported, and no remaining derivative positions listed. Future Form 4 filings will show whether this is an isolated liquidity event or part of a broader pattern of CEO share dispositions.

Insider Trade Summary

Net Seller: 150,000 shares ($2,752,163)

Net Sell 2 txns

Insider Santos da Silva Jorge

Role Chief Executive Officer

Sold 150,000 shs ($2.75M)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	51,873	$18.23	$946K
Sale	Class A ordinary shares, par value $0.0001 per share	98,127	$18.41	$1.81M

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 2,924,893 shares (Direct)

Footnotes (1)

1. Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $19.55. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Total shares sold: 150,000 shares Shares sold on April 10: 98,127 shares Weighted average price on April 10: $18.41 per share +3 more

6 metrics

Total shares sold 150,000 shares Open-market sales reported in this Form 4

Shares sold on April 10 98,127 shares Non-derivative Class A ordinary shares

Weighted average price on April 10 $18.41 per share Multiple transactions between $18.00 and $19.55

Shares sold on April 13 51,873 shares Non-derivative Class A ordinary shares

Weighted average price on April 13 $18.23 per share Multiple transactions between $18.00 and $18.41

Shares held after transactions 2,924,893 shares Direct ownership by CEO following sales

Key Terms

Rule 144, weighted average sale price, Class A ordinary shares, open-market sale

4 terms

Rule 144 regulatory

"Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos da Silva Jorge

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	04/10/2026		S		98,127	D(1)	$18.41(2)	2,976,766	D
Class A ordinary shares, par value $0.0001 per share	04/13/2026		S		51,873	D(1)	$18.23(3)	2,924,893	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $19.55. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MoonLake Immunotherapeutics (MLTX) CEO sell in this Form 4?

MoonLake Immunotherapeutics’ CEO, Jorge Santos da Silva, sold a total of 150,000 Class A ordinary shares. The transactions were open-market sales reported as non-derivative trades, reducing but not eliminating his direct equity stake in the company.

On what dates did the MoonLake (MLTX) CEO share sales occur?

The CEO’s reported share sales occurred on April 10 and April 13. Each day’s activity was disclosed separately, with the filing showing distinct transactions and weighted average prices for the Class A ordinary shares sold on those dates.

What prices did the MoonLake (MLTX) CEO receive for the sold shares?

The filing reports weighted average sale prices of $18.41 per share for the April 10 trades and $18.23 per share for the April 13 trades. Footnotes explain these are averages across multiple executions within specified intraday price ranges.

How many MoonLake (MLTX) shares does the CEO still own after these sales?

After the reported transactions, the CEO directly owns 2,924,893 Class A ordinary shares. This post-transaction figure in the filing shows he retains a substantial continuing equity position in MoonLake Immunotherapeutics despite the recent sales.

Were the MoonLake (MLTX) CEO share sales made under Rule 144?

Yes. A footnote states the CEO’s sales were made pursuant to Rule 144 under the Securities Act of 1933. Rule 144 provides a framework allowing insiders and other holders to resell restricted or control securities publicly if certain conditions are satisfied.

Do the MoonLake (MLTX) Form 4 trades involve derivatives or option exercises?

No. All reported transactions involve non-derivative Class A ordinary shares, coded as open-market sales. The derivative section is empty in this filing, indicating no option exercises, conversions, or other derivative transactions were reported alongside these sales.